R&D Center

PCG-BIOTECH aims to develop innovative anticancer drugs with fewer side effects.

Research Content

Excellence of epigenetic targets in new drug discovery

New Paradigm : "Epigenetic Regulation Control the fate of cells from normal to disease"

Multiple cancers are due to abnormalities in epigenetic modifiers.
Epigenetictarget drugs are first-in-class drugs that treat cancers that have been difficult to treat in the past.We developed a low-toxicity drug with no side effects targeting epigenetic modifiers.

Representative drug discovery disease target

Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia

  • PCG-C001


  • Healthy

  • AML

Excellence and competitiveness (First-In-Class) of
Acute Myeloid Leukemia (AML) target

Triple-Negative Breast Cancer (TNBC) Triple Negative Breast Cancer

  • PCG-C002

    Neutralizing Ab/ADC

  • PCG-C003


Excellence and competitiveness (First-In-Class) of
Triple-Negative Breast Cancer (AML) target

Metastatic Colon Cancer (CC)

  • PCG-C004

    Neutralizing Ab/ADC

Excellence and competitiveness (First-In-Class) of Colon Cancer target